Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27246692 | 0.98 | TAAR1 (0.40) | TAAR1ALDH1A1CYP3A4SMN1; SMN2SLC6A4 | |
| SCHEMBL18124641 | 0.84 | MAPK8 (0.46) | SMN1; SMN2NPC1RAB9AMAPK8LARS1 | |
| SCHEMBL1464593 | 0.83 | CYP3A4 (0.39) | TAAR1ALDH1A1CYP3A4SMN1; SMN2SLC6A4 | |
| SCHEMBL1465595 | 0.81 | NPC1 (0.40) | ALDH1A1CYP3A4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5024362 | 0.81 | ALDH1A1 (0.45) | TAAR1ALDH1A1CYP3A4SMN1; SMN2SLC6A4 | |
| SCHEMBL1465462 | 0.77 | ALDH1A1 (0.36) | TAAR1ALDH1A1CYP3A4SMN1; SMN2NPC1 | |
| SCHEMBL5018742 | 0.77 | TAAR1 (0.41) | TAAR1ALDH1A1CYP3A4SMN1; SMN2SLC6A4 | |
| SCHEMBL12219465 | 0.77 | CYP3A4 (0.36) | TAAR1ALDH1A1CYP3A4SMN1; SMN2SLC6A4 | |
| SCHEMBL21370005 | 0.75 | CYP3A4 (0.41) | ALDH1A1CYP3A4NPC1RAB9AMEN1 | |
| SCHEMBL11081166 | 0.74 | AHR (0.47) | ALDH1A1CYP3A4SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197694-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-06-20 | — | — | US | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | TAAR1 4278/4885ALDH1A1 2806/4885CYP3A4 1232/4885 |
| US-20240197694-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS | DCAF1, DDB1, CUL4A | TAAR1 3856/4885ALDH1A1 2985/4885CYP3A4 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.